¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Receptors, Interleukin-1 Type II"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • pyknic body type
    ´Ü½Åºñ¸¸½ÅüÇü
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • split-electrode-type probe
    ºÐÇÒÀü±Ø´õµëÀÚ
  • sthenic type
    ±Ù·ÂÇü
  • storage-type
    ÃàÀûÇü
  • swaged cast type crown
    ¾ÐÀÎÇü±Ý°ü
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü
  • simple type schizophrenia
    ´Ü¼øÇüÁ¤½ÅºÐ¿­º´
  • viral hepatitis type A
    AÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type B
    BÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type D
    DÇü¹ÙÀÌ·¯½º°£¿°
  • wild type
    ¾ß»ýÇü
  • wild type strain
    ¾ß»ýÁÖ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • intuitive type
    Á÷°üÇü
  • lepromatous type
    ³ªº´Á¾Çü
  • leptosomatic type
    ¸¶¸¥Çü
  • mating type
    ±³¹èÇü
  • meromyarian type
    ºÎºÐ±ÙÀ°Çü
  • plaque-type mutation
    ÇöóÅ©Çüµ¹¿¬º¯ÀÌ
  • nomenclatural type
    ºÐ·ùÇÐÀû±âÁظí
  • organic reaction type
    ±âÁú¹ÝÀÀÇü
  • ovulatory type
    ¹è¶õÇü
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • polymyarian type
    ´Ù±ÙÀ°Çü
  • propagative type
    Áõ½ÄÇü
  • pyknic body type
    ºñ¸¸½ÅüÇü
  • split-electrode-type probe
    ºÐÇÒÀü±Ø´õµëÀÚ
  • storage-type
    ÃàÀûÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Mobitz type II AV block
    ¸ðºñÃ÷ ¥±Çü ¹æ½ÇÂ÷´Ü.
  • Mobitz type II SA block
    ¸ðºñÃ÷ ¥±Çü µ¿¹æÂ÷´Ü.
  • Ogawa type
    ¿À°¡¿ÍÇü
  • RF coil type
    °íÁÖÆÄ ÄÚÀÏ À¯Çü
  • T-type channel
    T-Çü Åë·Î
  • aberrant type
    ÀÌÇü(ì¶úþ)
  • abortive type
    ºÎÀüÇü(ÝÕîïúþ).
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • agammaglobulinemia,x-linked, bruton type
    ¼º¿°»öü ¿¬°ü¼º, ºê·çÅæÇü(àõæøßäô÷ æáμàõ, ¡­úþ)
  • anovulatory type
    ¹«¹è¶õÇü
  • glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
  • golgi type i neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • golgi type ii neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • growth onset type diabetes
    Ãʱâ´ç´¢º´.
  • hebephrenic type
    ÆÄ°úÇü(÷òÍþúþ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cyclicodevelopmental type
    ÁÖ±âÀû ¹ßÀ°Çü(ÊÙËÑËôÌ´).
  • cyclicopropagative type
    ÁÖ±âÀû Áõ½ÄÇü(ÊÙÌ¡ËàÌ´).
  • delayed type hypersensitivity
  • delayed-type hypersensitivity
    Áö¿¬Çü °ú¹Î¹ÝÀÀ
  • demand type pacemaker
    ¼ö¿äÇü½É¹ÚÁ¶À²±â.
  • demblee type mycosis fungoides
    Àü°ÝÇü±Õ»ó½ÄÀ°Á¾
  • dementia of Alzheimers type
    ¾ËÃ÷ÇÏÀ̸ÓÇü Ä¡¸Å(~û¡ ö¸Å)
  • diagnostic type protective tube housing
    ÁøÂûÇü¹æÈ£¿ë ¿¢½º¼±°ü¿ë±â.
  • diploic type
    ÆÇ»çÀÌÇü, ÆÇ°£Çü(÷ùÊàúþ).
  • dorsolumbal type
    Èä¿äºÎ Çü(ýØé¦Ý»úþ), ¹èÃø ¿äºÎ Çü(ÛÎö°é¦Ý»úþ), ¹è¿ä Çü, Èä¿ä Çü.
  • dromedary type
    ´ÜºÀÇü.
  • dysplastic type
    ¹ßÀ°ºÎÀüü°Ý(Û¡ëÀÝÕîïô÷Ì«).
  • elastic type of artery
    ź·ÂÇüµ¿¸Æ
  • encephalopathy of multifocal type
    ´ÙÃÊÁ¡¼º ³úº´Áõ.
  • enchondral type
    ³»¿¬°ñ Çü(¡­úþ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AFB Acid-Fast Bacillus(Type that causes Tuberculosis)
DMD Duchenne type Muscular Dystrophy; ¾Ç¼ºÇü DuchenneÇü ±ÙÀÌ¿µ¾çÁõ
EA   1) Esophageal Atresia
  Types
  1. Esophageal Atresia with Dis...
GIDAANT Gender Identity Disorder of Adolescence or Adulthood, Non-transsexual Type
HBPV Haemophilus influenza type B Polysaccharide(PRP) Vaccine; BÇü Çì¸ðÇʷ罺 ÀÎÇ÷翣ÀÚ ÇǸ· ´Ù´çÁú ¹é½Å...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
hPR Human progesterone receptors
IPR Imidazolines Preferring Receptors
IFN-gamma R Interferon gamma receptors
KIR Killer cell Ig-like Receptors
KIR Killer cell Immunoglobulin-like Receptors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • knife edge type
    ³ªÀÌÇÁ ¿¡Âî ŸÀÔ
    finishing lineÀÇ ÀÏÁ¾ÀÌ´Ù.
  • lepromatous type
    ³ªÁ¾Çü
  • localized type
    ±¹¼ÒÇü
  • major type
    ÁÖµÈ ÇüÅÂ
  • membrane type
    ¸·Çü
  • mesial step type
    ±Ù½É °è´ÜÇü
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü
  • morphea-like type
    ¹Ý»ó °æÇÇÁõ °°Àº ÇüÅÂ
  • multifocal type
    ´Ù¹ß¼º
  • muscle tension type headache
    ±Ù ±äÀ强 µÎÅë
    ÈĵκÎ, Ç׺ÎÀÇ Áö¼ÓÀûÀÎ ¾Ð¹Ú°¨, ±³¾×°¨À» È£¼ÒÇÑ´Ù. ÀÌ ÁõÀÇ È¯ÀÚ´Â ½Å°æÁú·Î ±äÀåÇϱ⠽¬¿î »ç¶÷¿¡°Ô ¸¹°í °³Ã¼ÀÇ ±Ù±äÀ强¼ÒÀΰú ¾î¿ï¾îÁ® ±ÙÀÇ Áö¼ÓÀû ¼öÃà°ú ±ÙÀÇ ¼øÈ¯ ºÎÀü ¡æ ÅëÁõ ¹°Áú ¹ß»ý ¡æ ÅëÁõ ¡æ ±Ù ¼öÃàÀ̶ó´Â ¾Ç¼øÈ¯ÀÌ Çü¼ºµÇ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù. Á÷¾÷¿¡ µû¸¥ ºÎÀÚ¿¬½º·¯¿î ÀÚ¼¼°¡ °ü·ÃÀÌ ÀÖ´Â °æ¿ìµµ ¸¹°í ½Åü, ½É¸®Àû ¾çÃø¸éÀ¸·ÎºÎÅÍÀÇ Á¢±ÙÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹´Ù.
  • muscular type of vein
    ±ÙÀ°Çü Á¤¸Æ
  • nonnecrotizing type
    ºñ±«»ç¼º ÇüÅÂ
  • oral-facial-digital syndrome, type I
    IÇü±¸-¾È¸é-ÁöÁõÈıº
    X-¿¬°ü¼º ¿ì¼º À¯Àüº´À¸·Î¼­ ³²ÀÚ¿¡°Ô´Â Ä¡¸íÀûÀ¸·Î ±¼ÁöÁõ, ´ÙÁöÁõ, ÇÕÁöÁõ µîÀÌ Æ¯Â¡À̸ç, µÎ°³, ¾È¸é, ¼³, ±¸°³ ¹× ÇÏ¾Ç ±âÇüÀ» ¼ö¹ÝÇϰųª Áö´É ÀúÇÏ, Å»¸ðÁõ, ¾È¸é Áö·ç¸¦ ¼ö¹ÝÇÑ´Ù.
  • pedunclated type
    À¯°æÇü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
receptors, calcitonin Cell surface proteins that bind calcitonin and trigger intracellular changes which influence the behaviour of cells. Calcitonin receptors outside the nervous system mediate the role of calcitonin in calcium homeostasis. The role of calcitonin receptors in the brain is not well understood.
(12 Dec 1998)
receptors, calcitonin gene-related peptide Cell surface proteins that bind calcitonin gene-related peptide (cgrp) with high affinity and trigger intracellular changes which influence the behaviour of cells. Cgrp receptors are present in both the central nervous system and the periphery and are not the same as calcitonin receptors.
(12 Dec 1998)
receptors, calcitriol Proteins, usually found in the cytoplasm, that specifically bind calcitriol, migrate to the nucleus, and regulate transcription of specific segments of DNA. Vitamin d is converted in the liver and kidney to calcitriol and ultimately acts through these receptors.
(12 Dec 1998)
receptors, catecholamine Cell surface proteins that bind catecholamines with high affinity and trigger intracellular changes which influence the behaviour of cells. The catecholamine messengers epinephrine, norepinephrine, and dopamine are synthesised from tyrosine by a common biosynthetic pathway.
(12 Dec 1998)
receptors, ccr5 Seven-transmembrane G-protein-coupled receptors for beta-chemokines. They also function as fusion cofactors for macrophage-tropic HIV-1 strains.
(12 Dec 1998)
receptors, cell surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behaviour of the target cell. Cell surface receptors, unlike enzymes, do not chemically alter their ligands.
(12 Dec 1998)
receptors, chemokine Cell surface glycoproteins that bind to chemokines and thus mediate the migration of pro-inflammatory molecules. The receptors are members of the seven-transmembrane G-protein-coupled receptor family.
(12 Dec 1998)
receptors, cholecystokinin Cell surface proteins that bind cholecystokinin (cck) with high affinity and trigger intracellular changes influencing the behaviour of cells. Cholecystokinin receptors are activated by gastrin as well as by cck-4, cck-8, and cck-33. Activation of these receptors evokes secretion of amylase by pancreatic acinar cells, acid and pepsin by stomach mucosal cells, and contraction of the pylorus and gall bladder. The role of the widespread cck receptors in the central nervous system is not well understood.
(12 Dec 1998)
receptors, cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behaviour of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology.
(12 Dec 1998)
receptors, colony-stimulating factor Cell surface receptors for colony-stimulating factors, local mediators, and hormones that regulate the survival, proliferation, and differentiation of haemopoietic cells.
(12 Dec 1998)
receptors, complement Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement.
(12 Dec 1998)
receptors, complement 3b Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
(12 Dec 1998)
receptors, complement 3d Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor.
(12 Dec 1998)
receptors, concanavalin a Glycoprotein moieties on the surfaces of cell membranes that bind concanavalin a selectively; the number and location of the sites depends on the type and condition of the cell.
(12 Dec 1998)
receptors, corticotropin Cell surface receptors that bind corticotropin (acth, adrenocorticotropic hormone) with high affinity and trigger intracellular changes. Pharmacology suggests there may be multiple acth receptors. An acth receptor has been cloned and belongs to a subfamily of g-protein-coupled receptors. In addition to the adrenal cortex, acth receptors are found in the brain and immune systems.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á